^
Association details:
| Biomarker: | MTOR mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Torisel (temsirolimus) (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic Renal Cell Carcinoma
Excerpt:
Mutations in MTOR, TSC1 or TSC2 were more common in responders, 12 (28%) of 43, than non-responders, 4 (11%) of 36 (p=0.06). Mutations in TSC1 or TSC2 alone were also more common in responders, 9 (21%), than non-responders, 2(6%), (p=0.05). Furthermore, 5 (42%) of 12 subjects with PR had mutations in MTOR, TSC1 or TSC2 compared to 4 (11%) of 36 non-responders (p=0.03)...Thirty-eight (48%) were treated with everolimus and 41 (52%) received temsirolimus.
DOI:
10.1158/1078-0432.CCR-15-2631
